Nervous System Symptoms Associated With COVID 19

Not Applicable

Completed

• Conditions: Covid19
• Interventions: Other: NEURO +; Other: NEURO -

• Registration Number: NCT04922905
• Lead Sponsor: University Hospital, Toulouse

Brief Summary

This study aim to prospectively evaluate the neuropsychiatric symptoms of patients infected with the SARS-CoV-2 virus by a standardized neuropsychiatric examination : the global CASE scale (Clinical Assessment Scale in Autoimmune Encephalitis), and the prevalence of disturbances of consciousness, focal neurological deficit, cognitive impairment, headache, anosmia, sleep disturbances, impaired autonomic nervous system and peritraumatic stress.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-02
• Primary Completion: 2020-05-07
• Study Completion: 2021-04-02
• Status Verified: 2021-06
• Study First Submitted: 2021-06-09
• Study First Submitted QC: 2021-06-09
• Last Update Submitted: 2021-06-09
• Study First Posted: 2021-06-11
• Last Update Posted: 2021-06-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 99

Inclusion Criteria

• Being hospitalized at the Toulouse University Hospital for a COVID-19 infection proven by a probable PCR or COVID-type examination on the chest scan
• Have given oral consent for the collection of clinical neurological data
• Be in a clinical state compatible with a 30-minute neurological examination
• Be French-speaking
• Be affiliated to a Social Security scheme

Exclusion Criteria

• Refusal of the neurological examination
• History of neurological pathology at a severe stage
• Pregnant or breastfeeding woman
• Persons with tutors or curators

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
NEURO +	NEURO +	Patients "neuro +" are those with a CASE score ≥ 2, "Neuro +" patients will benefit from additional evaluations using paraclinical examinations
NEURO -	NEURO -	Patients "neuro -" are those with a CASE score \< 2

Primary Outcome Measures

Name	Time	Method
percentage of patients in the Neuro + and Neuro- groups	Baseline T0 : inclusion visit	The percentage is deducted from the score on a global scale by the Clinical Assessment Scale in Autoimmune Between 0 and 1, patients will be classified in the Neuro group, if this score is greater than or equal to 2, patients will be classified in the Neuro + group.

Trial Locations

Locations (1)

CHU Toulouse; 🇫🇷 Toulouse, France